Gestational Trophoblastic Neoplasm (GTN)

Categories: Cancer diseases, Rare diseases, Reproductive diseases

Aliases & Classifications for Gestational Trophoblastic Neoplasm

MalaCards integrated aliases for Gestational Trophoblastic Neoplasm:

Name: Gestational Trophoblastic Neoplasm 12 52 58 15
Hydatidiform Mole 12 43 15 71
Gestational Trophoblastic Disease 52 43 71
Gestational Trophoblastic Tumor 52 54
Gtn 52 58
Gestational Trophoblastic Neoplasia 12
Gestational Trophoblastic Neoplasms 71
Hydatidiform Mole, Recurrent, 1 71
Molar Pregnancy 12


Orphanet epidemiological data:

gestational trophoblastic neoplasm
Inheritance: Not applicable; Age of onset: Adult; Age of death: adult;


Orphanet: 58  
Rare gynaecological and obstetric diseases

External Ids:

Disease Ontology 12 DOID:3590
ICD9CM 34 630
ICD10 32 O01 O01.0 O01.9
MESH via Orphanet 44 D031901
UMLS via Orphanet 72 C1135868
Orphanet 58 ORPHA59305
SNOMED-CT via HPO 68 17369002 314631008 351814001
UMLS 71 C0020217 C0278796 C1135868 more

Summaries for Gestational Trophoblastic Neoplasm

NIH Rare Diseases : 52 The following summary is from Orphanet , a European reference portal for information on rare diseases and orphan drugs. Orpha Number: 59305 Definition Gestational trophoblastic tumors (GTT) are malignant forms of gestational trophoblastic disease. The tumor always follows pregnancy, most often molar pregnancy (hydatidiform mole; see this term). Four histological subtypes have been described: invasive mole, gestational choriocarcinoma, placental site trophoblastic tumor and epithelioid trophoblastic tumor (see these terms). Epidemiology Exact annual incidence is not known but it is estimated to be about 1/1,000,000 women. Clinical description GTTs occur following hydatidiform moles (see this term) (15% of complete moles and about 3% of partial moles), following spontaneous miscarriage (1/150) or childbirth (1/40,000). Indicative signs are an absence of normalization or a secondary elevation of total serum chorionic gonadotropin (hCG) levels after evacuation of a hydatidiform mole (more than 60% of cases), persistent unexplained metrorrhagia following spontaneous miscarriage or voluntary termination of pregnancy (VTP) (about 30% of cases) and very occasionally, unexplained metrorrhagia in the weeks or months following normal childbirth or ectopic pregnancy (about 10% of cases). Exceptionally, metastasis may be a sign of the disease in women of childbearing age. Etiology The etiology of gestational trophoblastic tumors is not known. Identification of a GTT is based on a total serum hCG assay, which is recommended following hydatidiform moles in patients with metrorrhagia persisting for more than six weeks after pregnancy, and in any patient of childbearing age who has metastasis (lung, liver, brain, kidney, vagina) with no known primary tumor. Diagnostic methods Diagnosis of a post-molar GTT relies on one of the following four criteria: stable hCG levels (variation of less than 10%) with at least four weekly assays over a period of at least three weeks (days 1, 7, 14, 21), increase of at least 10% in hCG with at least three weekly assays over at least two weeks (days 1, 7, 14), persistence of detectable hCG values for more than six months following mole evacuation or based on histological diagnosis of a choriocarcinoma. Differential diagnosis GTTs must not be confused with hydatidiform moles (see this term) and, for choriocarcinomas, with non-gestational choriocarcinomas, which are most often ovarian. Management and treatment As soon as the diagnosis is made, staging must be performed to identify frequent metastases. Staging involves endovaginal pelvic color doppler ultrasound , pelvic and cerebral MRI , and abdominal/chest CT. A lung X-ray must be performed to calculate the FIGO 2000 score (International Federation of Obstetrics and Gynecology) in case of lung metastasis on CT. This score makes it possible to distinguish between low-risk GTTs (score of 6 or lower) and high-risk GTTs (score of 7 or higher). Management should be multidisciplinary and must be discussed by a panel of physicians in a specialized center. Low-risk tumors are treated by systemic single-agent chemotherapy , e.g. methotrexate (marketing authorization). High-risk tumors are treated first line with systemic multi-agent chemotherapy. Hysterectomy can of course not be considered for first-line treatment in women who wish to become pregnant, unless there is no option. Placental site trophoblastic tumors and epithelioid trophoblastic tumors are special cases: the FIGO score is not appropriate and total hysterectomy is the standard treatment as these tumors are usually chemo-resistant. Prognosis The overall recovery rate is around 99%. The prognosis is very closely related to the rapidity of diagnosis, the risk level of the tumor (low or high) and the suitability of treatment. Visit the Orphanet disease page for more resources.

MalaCards based summary : Gestational Trophoblastic Neoplasm, also known as hydatidiform mole, is related to partial hydatidiform mole and hydatidiform mole, recurrent, 1. An important gene associated with Gestational Trophoblastic Neoplasm is H19 (H19 Imprinted Maternally Expressed Transcript). The drugs Amifostine and Acyclovir have been mentioned in the context of this disorder. Affiliated tissues include placenta, lung and bone, and related phenotypes are spontaneous abortion and menometrorrhagia

Related Diseases for Gestational Trophoblastic Neoplasm

Diseases related to Gestational Trophoblastic Neoplasm via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 281)
# Related Disease Score Top Affiliating Genes
1 partial hydatidiform mole 35.3 NLRP7 KHDC3L
2 hydatidiform mole, recurrent, 1 33.1 NLRP7 KHDC3L H19 CGB5 CDKN1C
3 placental site trophoblastic tumor 33.0 PAM LGALS1 CSH2 CSH1 CGB5
4 triploidy 32.2 NLRP7 KHDC3L
5 trophoblastic neoplasm 31.3 LGALS1 H19 CSH2 CSH1 CGB5
6 choriocarcinoma 31.0 H19 CSH2 CSH1 CGB5 CDKN1C
7 placenta disease 30.8 LGALS1 CSH2 CSH1 CGB5
8 epithelioid trophoblastic tumor 30.8 CSH2 CSH1
9 corpus luteum cyst 30.8 CSH2 CSH1 CGB5
10 gestational choriocarcinoma 30.5 NLRP7 H19 CSH2 CSH1
11 silver-russell syndrome 29.6 ZFP57 PLAGL1 H19 CSH1 CDKN1C
12 beckwith-wiedemann syndrome 29.2 ZFP57 PLAGL1 OOEP NLRP7 NLRP5 NLRP2
13 recurrent hydatidiform mole 13.1
14 hydatidiform mole, recurrent, 2 13.1
15 hydatidiform mole, recurrent, 3 13.0
16 hydatidiform mole, recurrent, 4 13.0
17 pulmonary arteriovenous fistulas 11.7
18 hyperthyroidism, familial gestational 11.2
19 pre-eclampsia 11.0
20 eclampsia 10.9
21 hyperthyroidism 10.9
22 ectopic pregnancy 10.8
23 severe pre-eclampsia 10.7
24 chromosomal triplication 10.7
25 graves disease 1 10.7
26 placenta praevia 10.7
27 ovarian cyst 10.6
28 tetraploidy 10.6
29 infertility 10.6
30 pemphigoid gestationis 10.5
31 testicular trophoblastic tumor 10.5 CSH2 CSH1
32 ovarian hyperstimulation syndrome 10.5
33 gestational ovarian choriocarcinoma 10.5 CSH2 CSH1
34 choriocarcinoma of the testis 10.5 CSH2 CSH1
35 hemihyperplasia, isolated 10.5 H19 CDKN1C
36 non-gestational ovarian choriocarcinoma 10.4 CSH2 CSH1
37 47,xyy 10.4
38 rh isoimmunization 10.4 CSH2 CSH1
39 paternal uniparental disomy of chromosome 6 10.4 PLAGL1 HYMAI
40 non-gestational choriocarcinoma 10.4 CSH2 CSH1
41 migraine with or without aura 1 10.4
42 headache 10.4
43 wilms tumor predisposition 10.4 H19 CDKN1C
44 supine hypotensive syndrome 10.4 CSH2 CSH1
45 anencephaly 10.4
46 hydrops, lactic acidosis, and sideroblastic anemia 10.4
47 nephrotic syndrome 10.4
48 overgrowth syndrome 10.4
49 invasive mole 10.4
50 neutropenia 10.4

Graphical network of the top 20 diseases related to Gestational Trophoblastic Neoplasm:

Diseases related to Gestational Trophoblastic Neoplasm

Symptoms & Phenotypes for Gestational Trophoblastic Neoplasm

Human phenotypes related to Gestational Trophoblastic Neoplasm:

58 31
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 spontaneous abortion 58 31 hallmark (90%) Very frequent (99-80%) HP:0005268
2 menometrorrhagia 58 31 hallmark (90%) Very frequent (99-80%) HP:0400008
3 high maternal serum chorionic gonadotropin 58 31 hallmark (90%) Very frequent (99-80%) HP:0011433

Drugs & Therapeutics for Gestational Trophoblastic Neoplasm

Drugs for Gestational Trophoblastic Neoplasm (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 188)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Amifostine Approved, Investigational Phase 3 20537-88-6 2141
Acyclovir Approved Phase 3 59277-89-3 2022
Ribavirin Approved Phase 3 36791-04-5 37542
Palivizumab Approved, Investigational Phase 3 188039-54-5
Itraconazole Approved, Investigational Phase 3 84625-61-6 55283
Miconazole Approved, Investigational, Vet_approved Phase 3 22916-47-8 4189
Captopril Approved Phase 3 62571-86-2 44093
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
Caspofungin Approved Phase 3 162808-62-0, 179463-17-3 468682 2826718
Amphotericin B Approved, Investigational Phase 3 1397-89-3 14956 5280965
Sodium citrate Approved, Investigational Phase 3 68-04-2
Letrozole Approved, Investigational Phase 3 112809-51-5 3902
Nitroglycerin Approved, Investigational Phase 2, Phase 3 55-63-0 4510
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
Cisplatin Approved Phase 3 15663-27-1 84093 441203 2767
Etoposide Approved Phase 3 33419-42-0 36462
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
Carboplatin Approved Phase 3 41575-94-4 10339178 498142 38904
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
leucovorin Approved Phase 3 58-05-9 6006 143
Dactinomycin Approved, Investigational Phase 3 50-76-0 2019 457193
Levoleucovorin Approved, Investigational Phase 3 68538-85-2
Norgestimate Approved, Investigational Phase 3 35189-28-7 6540478
Estradiol Approved, Investigational, Vet_approved Phase 3 50-28-2 5757
Moxifloxacin Approved, Investigational Phase 3 151096-09-2, 354812-41-2 152946
Polyestradiol phosphate Approved Phase 3 28014-46-2
Ethinyl Estradiol Approved Phase 3 57-63-6 5991
Mycophenolic acid Approved Phase 3 24280-93-1 446541
Calcium Approved, Nutraceutical Phase 3 7440-70-2 271
Citric acid Approved, Nutraceutical, Vet_approved Phase 3 77-92-9 311
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
Enclomiphene Investigational Phase 3 15690-57-0
34 Immunologic Factors Phase 3
35 Liver Extracts Phase 3
36 Calcium, Dietary Phase 3
37 Hormones Phase 3
38 Radiation-Protective Agents Phase 3
39 Antibodies, Monoclonal Phase 3
40 Immunoglobulins Phase 3
41 Antibodies Phase 3
42 Hormone Antagonists Phase 3
43 Antiviral Agents Phase 3
protease inhibitors Phase 3
45 HIV Protease Inhibitors Phase 3
46 Chelating Agents Phase 3
47 Estrogens Phase 3
48 valacyclovir Phase 3
49 Cytochrome P-450 CYP3A Inhibitors Phase 3
50 Cytochrome P-450 Enzyme Inhibitors Phase 3

Interventional clinical trials:

(show top 50) (show all 83)
# Name Status NCT ID Phase Drugs
1 A Comparison of Single Versus Double Evacuation for Treatment of Hydatidiform Unknown status NCT01630954 Phase 4
2 Primary Surgery Plus Single Course Methotrexate Versus Primary Methotrexate for Treatment of Gestational Trophoblastic Neoplasms in Low Risk Cases Above 40y: a Randomized Controled Trial Unknown status NCT02606539 Phase 2, Phase 3 Methotrexate plus folinic acid alone
3 Comparison Between Rescue Regimen and High Dose Methotrexate in the Managment of Presistent Gestational Trophoplastic Neoplasia :( A Randomized Controlled Trial ) Unknown status NCT03280979 Phase 2, Phase 3 rescue regimen;high dose methotrxate
4 A Randomized Phase III Trial of Weekly Parenteral Methotrexate Versus "Pulsed" Dactinomycin as Primary Management for Low Risk Gestational Trophoblastic Neoplasia Completed NCT00003702 Phase 3 Methotrexate
5 The Efficacy of Methotrexate for the Prevention of Postmolar Gestational Trophoblastic Disease Among Patients With High-Risk Hydatidiform Mole Completed NCT01984099 Phase 3 Methotrexate;Vitamin B Complex
6 A Randomized Phase III Trial of Amifostine vs. No Treatment for Platinum Induced Peripheral Neuropathy Completed NCT00058071 Phase 3 amifostine trihydrate
7 A Phase III Multicenter Study of Cytomegalovirus Prophylaxis With Valacyclovir for the Prevention of Serious Fungal and Bacterial Infections Among Cytomegalovirus Seronegative Recipients of Cytomegalovirus Seropositive Sx Stem Cell Transplants Completed NCT00045292 Phase 3 acyclovir;acyclovir sodium;valacyclovir
8 A Randomized Double-Blind Placebo-Controlled Phase III Study To Evaluate The Safety And Efficacy Of Palivizumab Combined With Aerosolized Ribavirin Compared To Ribavirin Alone To Treat RSV Pneumonia In Patients With Bone Marrow Transplants (BMT) Completed NCT00014391 Phase 3 ribavirin
9 Phase III Study of Captopril in Patients Undergoing Autologous Bone Marrow/Stem Cell Transplantation Completed NCT00004230 Phase 3 captopril;cyclophosphamide
10 A Randomized, Comparative Study of Itraconazole Versus Fluconazole for Prevention of Aspergillus Infections in Peripheral Blood Stem Cell and Marrow Transplant Recipients Completed NCT00003883 Phase 3 fluconazole;itraconazole
11 Music Video and Adolescent/Young Adult Resilience During Transplant Completed NCT00305851 Phase 3
12 A Multicenter, Double-Blind, Randomized, Comparative Study To Evaluate The Safety, Tolerability, And Efficacy Of MK-0991 Versus (Amphotericin B) Liposome For Injection As Empirical Therapy In Patients With Persistent Fever And Neutropenia Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
13 A Strategic Study to Determine the Optimal Moment to Initiate Systemic Antifungal Therapy With Ambisome in Granulocytopenic Cancer Patients With Unexplained Fever Refractory to Empirical Antibacterials Completed NCT00003938 Phase 3 liposomal amphotericin B
14 Study On The Effects of Letrozole And Clomiphene Citrate For Induction of Ovulation In Polycystic Ovarian Syndrome(PCOS) Completed NCT01577017 Phase 3 Letrozole
15 A Prospective Randomized Multicenter Clinical Control Study of Hysteroscopic Repeat Curettage as the Primal Management of Low-risk Postmolar Gestational Trophoblastic Neoplasia Recruiting NCT03703271 Phase 3 Methotrexate
16 A Prospective Randomized Multicenter Clinical Control Study of Paclitaxel Plus Cisplatin as the First-line Chemotherapy in High Risk Gestational Trophoblastic Tumor Recruiting NCT02639650 Phase 3 Etoposide;actinomycin D;methotrexate;vincristine;cyclophosphamide;Paclitaxel;Cisplatin;Carboplatin
17 Women's Hospital, Zhejiang University School of Medicine Recruiting NCT03885388 Phase 2, Phase 3 MTX;MTX+ACTD
18 A Phase III Randomized Trial of Pulse Actinomycin-D Versus Multi-day Methotrexate for the Treatment of Low-Risk Gestational Trophoblastic Neoplasia Active, not recruiting NCT01535053 Phase 3 Leucovorin Calcium;Methotrexate
19 A Multicenter, Prospective, Randomized Trial of Methotrexate Single-dose Treatment and Methotrexate/Actinomycin-D Single-dose Treatment in Low-Risk Gestational Trophoblastic Neoplasia Active, not recruiting NCT01823315 Phase 3 MTX 1;MTX 2
20 Randomized, Double Blinded, Placebo-Controlled Trial of Antibacterial Prophylaxis for the Prevention of Bacterial Infections in the Post-Engraftment Phase After Allogeneic Hematopoeitic Stem Cell Transplantation Terminated NCT00324324 Phase 3 moxifloxacin hydrochloride;Placebo
21 A Randomized Study to Evaluate The Efficacy of Mycophenolate Mofetil Added to The Systemic Immunosuppressive Regimen First Used For Treatment of Chronic Graft-Versus-Host Disease Terminated NCT00089141 Phase 3 mycophenolate mofetil;placebo
22 Pulse Actinomycin-D as Salvage Therapy for Failed Low Risk Gestational Trophoblastic Neoplasia Completed NCT00003688 Phase 2
23 A Phase II Study to Determine the Response to Second Curettage as Initial Management for Persistent Low Risk, Non-metastatic Gestational Trophoblastic Neoplasia Completed NCT00521118 Phase 2
24 A Phase II Trial of Pemetrexed (Alimta) in the Treatment of Recurrent or Persistent Low Risk Gestational Trophoblastic Tumor Completed NCT00190918 Phase 2 Pemetrexed
25 A Phase I-II Safety, Tolerability And Pharmacokinetic Study Of Ravuconazole For Prophylaxis Of Invasive Fungal Infections In Patients Undergoing Non-Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation Completed NCT00064311 Phase 1, Phase 2 ravuconazole
26 Oral Beclomethasone Dipropionate Capsules for Treatment of Intestinal Graft-Versus-Host Disease: Compassionate Use in Patients With Contraindictions to High-Dose Immunosuppressive Therapy Completed NCT00010283 Phase 1, Phase 2 beclomethasone dipropionate
27 Phase II Clinical Trial Incorporating Alemtuzumab (Campath-1H) in Combination With FK506 and Methylprednisolone for Treatment of Severe Acute Graft vs Host Disease Completed NCT00109993 Phase 2 methylprednisolone;tacrolimus
28 Combination of Interleukin 11 (Neumega) With G-CSF to Mobilize Autologous Peripheral Blood Stem Cells (PBSC) Completed NCT00004157 Phase 2
29 Donor Lymphocyte Infusion (DLI) as Adoptive Immunotherapy for Relapse Malignancies After Allogeneic Hematopoietic Transplantation Completed NCT00003887 Phase 2
30 Cytokine-Based Immunotherapy Following High-Dose Chemotherapy and Autologous Stem Cell Transplantation Completed NCT00003408 Phase 2
31 A Phase II Study to Evaluate Low-Dose Alemtuzumab as a Glucocorticoid-Sparing Agent for Initial Systemic Treatment of Acute Graft-Versus-Host Disease Completed NCT00410657 Phase 2 methylprednisolone;prednisone
32 Psychosexual Intervention for Gynecologic and Breast Cancer Patients Completed NCT01764802 Phase 2
33 Prevention of DMSO-Related Nausea and Vomiting by Prophylactic Administration of Ondansetron for Patients Receiving Autologous Cryopreserved Peripheral Blood Stem Cells Completed NCT00795769 Phase 2 ondansetron
35 A Phase II Study to Evaluate Efficacy and Tolerability of Methotrexate in Combination With Glucocorticoids for the Treatment of Newly Diagnosed Acute Graft-Versus-Host Disease After Nonmyeloablative Hematopoietic Cell Transplantation Completed NCT00357084 Phase 2 methotrexate;methylprednisolone;prednisone
36 A Multicenter, Open, Phase II Study to Estimate the Activity and Safety of Caspofungin (CASP) in the First-Line Treatment of Probable and Proven Invasive Aspergillosis (IA) in Patients With Hematological Malignancies (HM) or Recipients of Autologous Haematopoietic Stem Cell Transplantation and Those With Allogeneic Haematopoietic Stem Cell Transplantation (HSCT) Completed NCT00110045 Phase 2 caspofungin acetate
37 Camrelizumab Combined With Apatinib for Recurrent Resistant Gestational Trophoblastic Neoplasia: a Phase 2, Single-arm, Prospective Study Recruiting NCT04047017 Phase 2 Apatinib;Camrelizumab
38 A Phase II Trial of Avelumab in Chemo-resistant Gestational Trophoblastic Neoplasias (GTN) Recruiting NCT03135769 Phase 2 Avelumab administration at 10mg/kg
39 DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors Recruiting NCT02834013 Phase 2
40 A Phase II Trial of Pemetrexed (ALIMTA®, LY231514, IND #40061) as Salvage Therapy for Failed Low Risk Gestational Trophoblastic Tumor Terminated NCT00096187 Phase 2 pemetrexed disodium
41 A Phase 2A Study of TRC105 (With Option to Add Bevacizumab) in Patients With Refractory Gestational Trophoblastic Neoplasia (GTN) Terminated NCT02664961 Phase 2 TRC105;Bevacizumab
42 Deferasirox Treatment and Labile Plasma Iron in Iron Overloaded Patients Who Have Undergone Allogeneic Hematopoietic Stem Cell Transplantation Terminated NCT01159067 Phase 2 deferasirox
43 A Phase I Clinical Trial of Intrapleural Adenoviral-Mediated Interferon-beta (IFN-ß) Gene Transfer for Pleural Malignancies Unknown status NCT00066404 Phase 1
44 Emergency Access to C.V. pp65 / IE-1 Specific Cytotoxic T Lymphocytes for Recipients of Allogeneic Stem Cell Transplants With Persistant or Therapy Refractory Infections Unknown status NCT00769613 Phase 1
45 A Phase I Trial of Recombinant Human Interleukin-12 After High-Dose Therapy and Autologous Hematopoietic Stem Cell Support Completed NCT00003107 Phase 1
46 Prolonged Infusion Compared to Standard Infusion Cefepime as Empiric Treatment of Febrile Neutropenia: A Pilot Study Completed NCT01484015 Phase 1 cefepime hydrochloride
47 Phase I Study of Intraperitoneal Administration of 9-Amino-20(S)-Camptothecin to Patients With Cancer Predominantly Confined to the Peritoneal Cavity Completed NCT00003548 Phase 1 aminocamptothecin colloidal dispersion
48 A Phase I Study of Thrombopoietin (rhTPO) Plus G-CSF in Children Receiving Ifosfamide, Carboplatin, and Etoposide (I.C.E.) Chemotherapy for Recurrent or Refractory Solid Tumors Completed NCT00003597 Phase 1 carboplatin;etoposide;ifosfamide
49 Donor Natural Killer Cell Infusion for the Prevention of Relapse or Graft Failure After HLA-Haploidentical Familial Donor Bone Marrow Transplantation-A Phase I Study Completed NCT00569283 Phase 1
50 A Phase I Trial to Examine the Safety, Clinical, Immunologic and Virologic Effects of CMV pp65 Specific Cytotoxic T Lymphocytes for Recipients of Allogeneic Stem Cell Transplants With Persistent or Therapy Refractory Infections Completed NCT00509691 Phase 1

Search NIH Clinical Center for Gestational Trophoblastic Neoplasm

Cochrane evidence based reviews: hydatidiform mole

Genetic Tests for Gestational Trophoblastic Neoplasm

Anatomical Context for Gestational Trophoblastic Neoplasm

MalaCards organs/tissues related to Gestational Trophoblastic Neoplasm:

Placenta, Lung, Bone, Testes, Liver, Bone Marrow, Uterus

Publications for Gestational Trophoblastic Neoplasm

Articles related to Gestational Trophoblastic Neoplasm:

(show top 50) (show all 2777)
# Title Authors PMID Year
Criteria for initiating chemotherapy in patients after evacuation of hydatidiform mole. 54 61
14610317 2003
A challenging case of twin pregnancy with complete hydatidiform mole and co-existing normal live fetus - A case report and review of the literature. 61
31890831 2020
Complete Hydatidiform Mole Mimicking Sacroiliitis. 61
32000225 2020
Complete Hydatidiform Mole and Co-Existing Live Fetus after Intracytoplasmic Sperm Injection: A Case Report and Literature Review. 61
31997691 2020
Parentage of Hydatidiform Moles. 61
31999355 2020
Identification of a hydatidiform mole in twin pregnancy following assisted reproduction. 61
31833013 2019
A KHDC3L mutation resulting in recurrent hydatidiform mole causes genome-wide DNA methylation loss in oocytes and persistent imprinting defects post-fertilisation. 61
31847873 2019
Comprehensive analysis of 204 sporadic hydatidiform moles: revisiting risk factors and their correlations with the molar genotypes. 61
31857680 2019
Loss of p57KIP2 expression confers resistance to contact inhibition in human androgenetic trophoblast stem cells. 61
31792181 2019
[Clinical characteristics and diagnosis of early hydatidiform mole]. 61
31752459 2019
Gestational Trophoblastic Neoplasia, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. 61
31693991 2019
Improved assembly and variant detection of a haploid human genome using single-molecule, high-fidelity long reads. 61
31711268 2019
A case report of pelviscopic resection of invasive hydatidiform mole. 61
31593140 2019
Complete hydatidiform mole with a twin pregnancy at 26 weeks: a rare obstetric complication. 61
31641655 2019
Heuristic neural network approach in histological sections detection of hydatidiform mole. 61
31720313 2019
Termination of a partial hydatidiform mole and coexisting fetus: A case report. 61
31667181 2019
Is a Complete Hydatidiform Mole and a Co-existing Normal Fetus an Iatrogenic Effect? 61
31599505 2019
Microsatellite DNA Genotyping and Flow Cytometry Ploidy Analyses of Formalin-fixed Paraffin-embedded Hydatidiform Molar Tissues. 61
31680667 2019
Overexpression of iASPP is required for autophagy in response to oxidative stress in choriocarcinoma. 61
31615473 2019
Choriocarcinoma After Normal Vaginal Delivery; A Rare Entity. 61
31933325 2019
Whole transcriptome analysis of gestational trophoblastic neoplasms reveals altered PI3K signaling pathway in epithelioid trophoblastic tumor. 61
31954539 2019
Ovarian hyperstimulation syndrome following surgical removal of a complete hydatidiform mole: a case report. 61
31506106 2019
p57 in Hydatidiform Moles: Evaluation of Antibodies and Expression in Various Cell Types. 61
31567274 2019
Clinical characteristics and outcomes of extrauterine epithelioid trophoblastic tumors. 61
31312959 2019
Molecular cytogenetic analysis of a hydatidiform mole with coexistent fetus: a case report. 61
31421684 2019
Imaging in Gestational Trophoblastic Disease. 61
31375173 2019
Thyroid function among women with gestational trophoblastic diseases. A cross-sectional study. 61
31411244 2019
[Recurrent diploid biparental mole]. 61
31495354 2019
Persistent free-floating pelvic trophoblastic cysts following an interstitial ectopic pregnancy. 61
31439571 2019
A Novel Mutation in NLRP7 Related to Recurrent Hydatidiform Mole and Reproductive Failure. 61
31037924 2019
Avoid making a mountain out of an invasive hydatidiform mole: do a pregnancy test! 61
31327371 2019
Increased LIGHT leading to sFlt-1 elevation underlies the pathogenic link between hydatidiform mole and preeclampsia. 61
31300808 2019
Thiol/Disulfide Homeostasis in Patients with Molar Pregnancies. 61
31304870 2019
Expression of p57 immunomarker in the classification and differential diagnosis of partial and complete hydatidiform moles. 61
31579240 2019
Paternal uniparental isodisomy of tyrosine hydroxylase locus at chromosome 11p15.4: spectrum of phenotypical presentations simulating hydatidiform moles. 61
30952972 2019
A partial molar pregnancy associated with a fetus with intrauterine growth restriction delivered at 31 weeks: a case report. 61
31269962 2019
Spontaneous regression of quiescent gestational trophoblastic disease after pregnancy: a case report. 61
31337386 2019
Gestational trophoblastic neoplasms (GTNs) do not display epithelial-to-mesenchymal transition (EMT) features. 61
30847562 2019
31418743 2019
The potential value of red blood cell distribution width in patients with invasive hydatidiform mole. 61
30883924 2019
miR-196b inhibits cell migration and invasion through targeting MAP3K1 in hydatidiform mole. 61
30889489 2019
Interstitial pregnancy mimicking an invasive hydatidiform mole. 61
31079718 2019
A rare case of ovarian vein thrombosis in a gestational trophoblastic neoplasia patient. 61
31139597 2019
Gestational Trophoblastic Disease at Sultan Qaboos University Hospital: Prevalence, Risk Factors, Histological Features, Sonographic Findings, and Outcomes. 61
31110626 2019
Tubal hydatidiform mole treated with salpingotomy: A case report. 61
30997056 2019
Correction to: ''Bunch of grapes'' in complete hydatidiform mole. 61
30284604 2019
Inter-observer variability in the histologic criteria of diagnosis of hydatidiform moles. 61
31025633 2019
Genetically Related Choriocarcinoma Developing 5 Yr After a Complete Hydatidiform Mole and Simulating a Cornual Ectopic Pregnancy. 61
31033803 2019
The management of hydatidiform mole with lung nodule: a retrospective analysis in 53 patients. 61
30740949 2019
Do we need post-pregnancy screening with human chorionic gonadotrophin after previous hydatidiform mole to identify patients with recurrent gestational trophoblastic disease? 61
30684876 2019

Variations for Gestational Trophoblastic Neoplasm

Expression for Gestational Trophoblastic Neoplasm

Search GEO for disease gene expression data for Gestational Trophoblastic Neoplasm.

Pathways for Gestational Trophoblastic Neoplasm

GO Terms for Gestational Trophoblastic Neoplasm

Cellular components related to Gestational Trophoblastic Neoplasm according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.23 PRB1 PAM LGALS1 CTSC CSH2 CSH1

Biological processes related to Gestational Trophoblastic Neoplasm according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 apoptotic process GO:0006915 9.72 PLAGL1 NLRP2 LGALS1 CTSC CGB5
2 positive regulation of JAK-STAT cascade GO:0046427 9.37 CSH2 CSH1
3 adrenal gland development GO:0030325 9.26 NR0B1 CDKN1C
4 animal organ development GO:0048513 9.16 CSH2 CSH1
5 growth hormone receptor signaling pathway GO:0060396 8.96 CSH2 CSH1
6 positive regulation of growth GO:0045927 8.62 CSH2 CSH1

Molecular functions related to Gestational Trophoblastic Neoplasm according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth hormone receptor binding GO:0005131 8.62 CSH2 CSH1

Sources for Gestational Trophoblastic Neoplasm

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
54 Novoseek
57 OMIM via Orphanet
61 PubMed
70 Tocris
72 UMLS via Orphanet
Loading form....